II ) : a randomized trial to determine whether HLA class II matching reduces the risk of allograft rejection in penetrating keratoplasty

Armitage WJ, Winton HL, Jones MNA, Downward L, Crewe JM,Rogers CA, Tole DM, Dick AD Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK NHS Blood & Transplant, Bristol, UK Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK Bristol Eye Hospital, Bristol, UK School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK Corresponding author: Professor W John Armitage Translational Health Sciences, Bristol Medical School University of Bristol Bristol Eye Hospital Lower Maudlin Street Bristol BS1 2LX United Kingdom Email: w.j.armitage@bristol.ac.uk